3 Comments
author

Tokuyama M, Gunn BM, Venkataraman A, Kong Y, Kang I, Rakib T, Townsend MJ, Costenbader KH, Alter G, Iwasaki A. Antibodies against human endogenous retrovirus K102 envelope activate neutrophils in systemic lupus erythematosus. J Exp Med. 2021 Jul 5;218(7):e20191766. doi: 10.1084/jem.20191766. Epub 2021 May 21. Also a sightly different preprint is available at https://doi.org/10.1101/776468 Sept 20, 2019. This paper claims most of the antibody to HERV-K102 is IgG2 with some IgG1.. The complex of soluble HERV-K102 Env (SU domain) with IgG2 antibody activates neutrophils via the FCGR3B (CD16b). SLE plasma (or purified IgG) and recombinant HERV-K102 SU Env form a complex which activates neutrophils: enhances antibody dependent neutrophil phagocytosis (shown by flow cytometry) and increases Neutrophil Extracellular Trap (NET) formation; shown by microscope for fluorescence following Hoeschst staining for extracellular DNA, citrullinated histone 3, and neutrophil elastase.

Expand full comment

Compare President Trump's experience with the original monoclonal antibodies to Joe Biden's Paxlovid-induced rebound Covid.

As your title indicates, the original monoclonal antibodies are now ineffective against the Omicron-series variants' spike proteins. I believe that the Americans have "deauthorized" the original monoclonals and sent them for disposal. However, they should still have been useful against Vaxx injury from the initial injections which should have induced the original spikes (if we were confident that we knew what was truly in the vials.)

I can't get as deeply into the literature as you are able, but I haven't seen anything to suggest that such a treatment has been studied. The FLCCC website does not list this in their long covid or vaxx injury segments.

Expand full comment